BiotechTube
Biofabri

Biofabri

Porriño, Spain· Est.
biofabri.es
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Biofabri is a private, clinical-stage biotech company developing next-generation vaccines and immunotherapies. Its lead asset, MTBVAC, is a promising tuberculosis vaccine candidate that has progressed to Phase 2 clinical trials and aims to improve upon the century-old BCG vaccine. The company leverages a broad technology platform spanning classic, genetically engineered, subunit, and nucleic acid-based vaccines to address significant infectious diseases and oncology indications. As part of the Zendal Group, Biofabri benefits from integrated manufacturing and development capabilities within the larger organization.

Infectious DiseasesOncology

Technology Platform

Multi-platform vaccine developer with expertise in classic, live-attenuated, recombinant subunit, and nucleic acid (RNA/DNA) vaccine technologies.

Funding History

1
GrantUndisclosed

Opportunities

MTBVAC addresses a massive unmet medical need in tuberculosis, with the potential to replace the 100-year-old BCG vaccine and protect adults, accessing a multi-billion dollar global health market.
The company's broad vaccine technology platform allows for expansion into other high-burden infectious diseases and immuno-oncology.

Risk Factors

The lead program faces significant clinical trial risk, as TB vaccine development has a high historical failure rate.
As a pre-revenue company, Biofabri is dependent on continued funding from its parent group and future partners to finance expensive late-stage trials and commercialization.

Competitive Landscape

In tuberculosis, Biofabri's MTBVAC competes with other candidates, most notably the GSK/IAVI M72/AS01E subunit vaccine, which has reported positive Phase 2b efficacy data. In bladder cancer immunotherapy, the market is dominated by the standard BCG therapy, but faces frequent supply shortages, creating an opening for reliable alternatives.

More companies in Biologics / Biosimilars →More companies in Spain →